

STATE OF MISSOURI

## BUREAU OF IMMUNIZATIONS COVID-19 VACCINATION SCREENING AND CONSENT UNDER EMERGENCY USE AUTHORIZATION

Please complete the following information for the person receiving the COVID-19 vaccine.

PATIENT DEMOGRAPHIC INFORMATION									
LAST NAME: FIRST NAME:					MIDDLE INITIAL:				
DATE OF BIRTH:	SEX:								
RACE: HISPANIC ETHNICITY:									
White Black Asian Pacific Islander	_		_						
American Indian/Alaskan Native None Specified	Refused	Unknown	Refused	1					
ADDRESS: CITY:									
STATE: ZIP: HOME PH	HONE:		CELL PHONE:						
EMAIL:	WOU	LD LIKE A REMINDER FOR TH	E NEXT APPOINT	MENT:					
		☐ Yes ☐ No Postcard/call/text							
Private or employer insurance Underinsured Uninsured Medicare Medicaid									
Phase 1B - Tier 1 Worker Information: Protecting those who keep us safe and help during emergencies									
🗌 First Responders 🛛 Non-Patient Facing Public Health Infrastructure 🖓 Emergency Management and Public Works									
Emergency Services Sector									
Phase 1B - Tier 2 High-Risk Individuals: Protecting those who are at increased risk for severe illness									
Anyone aged 65 and older									
Any Adult with the following conditions: Cancer, Chronic Kidney Disease, COPD (chronic obstructive pulmonary disease), Intellectual and/or developmental disabilities such as									
Down Syndrome, Heart Conditions (such as heart failure, coronary artery disease, or cardiomyopathies), Immunocompromised state from solid organ transplant, Severe Obesity (BMI greater than 40), Pregnancy, Sickle Cell Disease, &/or Type 2 Diabetes Mellitus									
Phase 1B - Tier 3 Critical Infrastructure Workers: Protecti									
Education (K-12) Childcare Communicati	-	Dams Sec		Energy Sector	-				
□ Information Technology Sector □ Nuclear Reactors, Materials, and Waste Sector □ Transportation Systems Sector □ Water and Wastewater Systems Sector									
Government: Certain elected/appointed officials or other personnel designated by the executive, legislative, and judicial branches of									
state government									
Group Food/Agriculture Sector – initial: Employees of certain food production and processing facilities, and related operations, prioritizing mass									
food production, distribution, transportation, wholesale, veterinary serves, and retail sales.									
Phase 2, Equity & Economic Recovery: Protecting those	e who have	been disproportion	ately affecte	ed and accelerati	ng economic				
	0				ial Dana Oratan				
Chemical Sector	Sector	Critical Manufacturi			ial Base Sector				
□ Financial Services Sector □ Higher Education □ Disproportionately Affected □ Homeless									
Government: Other state and local government designated personnel required to provide essential services Food/Agriculture Sector II: Remaining populations within the sector not included in 1B, including restaurants									
		,							
Phase 3, Remaining Unvaccinated Populations: Protecting everyone else who has not been vaccinated, but wants to do so Resident who doesn't fall into the above phases/tiers									
The State of Missouri is conducting a phased roll out of the C		ooino prioritizina covi	na livos and i	is distated by yac	vino availability				
The State of Missouri is conducting a phased roll-out of the COVID-19 vaccine prioritizing saving lives and is dictated by vaccine availability. This form will gather information about you, including your employment and health risks to determine your eligibility and properly schedule your									
vaccination appointment. All your information will be kept confidential to the extent allowed by law. By signing below you are self-certifying									
that everything you have indicated on this form is true and that you fall into the phase/tier indicated above.									
Specific information about the populations within each phase/tiers can be found on the MOStopsCovid.com website.									
· · · · · · · ·			300via.com						
SIGNATURE/GUARDIAN	RE	ELATIONSHIP TO CLIENT		TODAY'S DATE					
Clinical Judgement – all vaccinators are encourage to use their clinical judgement/discretion to authorize a vaccine for any individual,									
regardless of where they may otherwise fall in the prioritization process.									
PROVIDER SIGNATURE	•			DATE					

HEALTH HISTORY			YES	NO	<u>UNKNOWN</u>				
1. Are you feeling sick today?									
2. Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something?									
For example, a reaction for which you were treated with epinephrine or Epi Pen or for which you had to go to the hospital?									
3. Have you ever had a serious reaction after any vaccination or injectable medication including a previous dose of the COVID-19 vaccine?									
4. In the past 14 days have you had contact with a confirmed COVID-19 patient?									
5. Are you breastfeeding or pregnant?									
6. Have you received passive antibody therapy as a treatment for COVID-19?									
7. Are you immunocompromised? (taking medication or being treated for cancer, leukemia, HIV/AIDS or other immune system problems or taking medication that affects your immune system)									
8. Do you have a bleeding disorder or are you taking a blood thinner?									
9. Have you ever received a dose of COVID-19 vaccine?									
If so, Date received									
The Public Readiness and Emergency Preparedness Act (PREP Act) authorizes the CICP to provide benefits to certain individuals or estates of individuals who sustain a covered serious physical injury as the direct result of the administration or use of the covered countermeasures. The CICP can also provide benefits to certain survivors of individuals who die as a direct result of the administration or use of covered countermeasures identified in a PREP Act declaration. The PREP Act declaration for medical countermeasures against COVID-19 states that the covered countermeasures are any antiviral medication, any other drug, any biologic, any diagnostic, any other device, or any vaccine used to treat, diagnose, cure, prevent, or mitigate COVID-19, the transmission of SARS-COV-2 or a virus mutating from SARS-CoV-2, or any device used in the administration of and all components and constituent materials of any such product. Information about the CICP and filing a claim is available by calling 1-855-266-2427 or visiting https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine or https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine									
PLEASE PRINT NAME of signature below									
SIGNATURE OF PATIENT RELATIONSHIP TO CLIENT					TODAY'S DATE				
ACKNOWLEDGMENT OF RECEIPT OF NOTICE OF PRIVACY PRACTICES									
I,, acknowledge and agree that I have received or have been advised of the Missouri Department of Health and PRINT NAME HERE Senior Services' Notice of Privacy Practices and where I can obtain any revisions made to this Notice.									
CLIENT SIGNATURE/LEGAL REPRESENTATIVE RELATIONSHIP TO CLIENT			TODAY'S DATE						
FOR CLINIC USE ONLY									
MANUFACTURER	BRAND		OT NUMBER						
	*EXP. DATE:		*DATE ADMINISTERED:						
*EUA FACT SHEET DATE:									
VACCINE DOSE:									
ADMINISTERED BY NAME & TITLE:									
AGENCY:									
AGENCY ADDRESS:									
CLINIC ADMINISTRATION ADDRESS									

## Information for healthcare Professionals about the health history for COVID-19 Vaccines

Are you feeling sick today? There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (e.g., upper respiratory infections, diarrhea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics. Vaccination of persons with current SARS-CoV-2 infection should be deferred until the person has recovered from acute illness and they can discontinue isolation. While there is no minimum interval between infection and vaccination, current evidence suggests reinfection is uncommon in the 90 days after initial infection. Persons with documented acute SARSCoV-2 infection in the preceding 90 days may delay vaccination until near the end of this period, if desired.

Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something? For example, a reaction for which you were treated with epinephrine or EpiPen®, or for which you had to go to the hospital? Allergic reactions, including severe allergic reactions, NOT related to vaccines or injectable therapies (e.g., food, pet, venom, environmental, or latex allergies; oral medications) are NOT a contraindication or precaution to vaccination with currently authorized COVID-19 vaccine. HOWEVER, individuals who have had severe allergic reactions to something, regardless of cause, should be observed for 30 minutes after vaccination. All other persons should be observed for 15 minutes.

Have you ever had a serious reaction after any vaccination or injectable mediation including a previous dose of the COVID-19 vaccine? History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of the COVID-19 vaccine product being offered is a contraindication to that COVID-19 vaccine. If the patient answers Yes to this question, defer vaccination for 90 days from date of therapy.

In the past 14 days have you had contact with a confirmed COVID-19 patient? Wait until 14 days after quarantine period ends if the contact was in an outpatient or community setting. If person is a resident in a congregate healthcare or other congregate setting go ahead and vaccinate

Are you breastfeeding or pregnant? Is not a contraindication to current COVID-19 vaccination. While there are currently no available data on the safety of COVID-19 vaccines in pregnant people, studies and results are expected soon. Pregnant people may choose to get vaccinated. Observational data demonstrate that while the absolute risk is low, pregnant people with COVID-19 have an increased risk of severe illness. Breastfeeding is not a contraindication to current COVID-19 vaccine. Lactating people may choose to be vaccinated. There is no data available for lactating people on the effects of mRNA vaccines.

Have you received passive antibody therapy as a treatment for COVID-19? Based on the estimated half-life of monoclonal antibodies or convalescent plasma as part of COVID-19 treatment, as well as evidence suggesting that reinfection is uncommon in the 90 days after initial infection, vaccination should be deferred for at least 90 days, as a precautionary measure until additional information becomes available, to avoid interference of the antibody treatment with vaccine-induced immune responses

Are you immunocompromised? (taking mediation or being treated for cancer, leukemia, HIV/AIDS or other immune system problems or taking medication that affects your immune system is not a contraindication to current COVID-19 vaccine, including those with cancer, leukemia, HIV/AIDS and other immune system problems or taking medication that affects their immune systems. However, patients should be informed that the vaccine might be less effective than in someone who is immunocompetent.

**Do you have a bleeding disorder or are you taking a blood thinner?** COVID-19 vaccine may be given to these patients, if a physician familiar with the patient's bleeding risk determines that the vaccine can be administered intramuscularly with reasonable safety. ACIP recommends the following technique for intramuscular vaccination in patients with bleeding disorders or taking blood thinners: a fine-gauge needle (23-gauge or smaller caliber) should be used for the vaccination, followed by firm pressure on the site, without rubbing, for at least 2 minutes.